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Platelet-derived Growth Factors (GFs) are biologically active peptides that enhance tissue repair mechanisms such as angiogenesis,
extracellular matrix remodeling, and cellular eﬀects as stem cells recruitment, chemotaxis, cell proliferation, and diﬀerentiation.
Platelet-richplasma(PRP)isusedinavarietyofclinicalapplications,basedonthepremisethathigherGFcontentshouldpromote
better healing. Platelet derivatives represent a promising therapeutic modality, oﬀering opportunities for treatment of wounds,
ulcers, soft-tissue injuries, and various other applications in cell therapy. PRP can be combined with cell-based therapies such as
adipose-derived stem cells, regenerative cell therapy, and transfer factors therapy. This paper describes the biological background
of the platelet-derived substances and their potential use in regenerative medicine.
1.Introduction
Platelets are nonnuclear cellular fragments derived from
megakaryocytes in the bone marrow; they are specialized
secretory elements that release the contents of their intracel-
lulargranulesinresponsetoactivation.Theywerediscovered
by Bizzozero in the 19th century [1]a n da f t e rW r i g h to b -
served that megakaryocytes are platelet precursors [2]. Actu-
ally we know that platelets synthesize proteins and that pat-
tern of peptides synthesis changes in response to cellular
activation [3].
Platelets contain a great variety of proteins molecules,
among which are the high presence of signaling, membrane
proteins, protein processing, cytoskeleton regulatory pro-
teins, cytokines, and other bioactive peptides that initiate
and regulate basic aspects of wound healing [3]. It is known,
through eﬀorts such as the platelet proteome project, that
more than 300 proteins are released by human platelets
in response to thrombin activation [4]. Proteome platelet
includes 190 membrane-associated and 262 phosphorylated
proteins, which were identiﬁed via independent proteomic
and phospho proteomic proﬁling [5].
When platelets fall precipitously below critical levels
(usually under 10,000 to 20,000 per cubic millimeter), mo-
lecular disassembly opens the zippers formed by adjacent
intercellular endothelial junctions, causing extravasation
of erythrocytes into the surrounding tissues. In addition
to their well-known function in hemostasis, platelets also
release substances that promote tissue repair, angiogene-
sis, and inﬂammation [6]. Furthermore, they induce the
migration and adherence of bone-marrow-derived cells to
sites of angiogenesis; platelets also induce diﬀerentiation of
endothelial-cellprogenitorsintomatureendothelialcells[7].
At the site of the injury, platelets release an arsenal
of potent regenerative and mitogenic substances that are
involved in all aspects of the wound-healing process includ-
ing a potential point-of-care biologic treatment following
myocardial injury [8]. Based on this, platelet called Platelet-
rich Plasma (PRP) has been extensively used for orthopaedic2 International Journal of Peptides
Table 1: Peptidic growth factors present in platelet-rich plasma (PRP).
Name Cytogenetic location Biologic activities
Transforming growth factor, beta-I; TGFB1 19q13.2 Controls proliferation, diﬀerentiation, and other
functions in many cell types
Platelet-derived growth factor, alpha polypeptide;
PDGFA 7p22.3
Potent mitogen for connective tissue cells and exerts
its function by interacting with related receptor
tyrosine kinases
Platelet-derived growth factor, beta polypeptide;
PDGFB 22q13.1 Promotes cellular proliferation and inhibits
apoptosis
Platelet-derived growth factor C; PDGFC 4q32.1
Increases motility in mesenchymal cells, ﬁbroblasts,
smooth muscle cells, capillary endothelial cells, and
neurons
Platelet-derived growth factor D; PDGFD 11q22.3
Involved in developmental and physiologic
processes, as well as in cancer, ﬁbrotic diseases, and
arteriosclerosis
Insulin-like growth factor I; IGF1 12q23.2 Mediates many of the growth-promoting eﬀects of
growth hormone
Fibroblast growth factor I; FGF1 5q31.3 Induces liver gene expression, angiogenesis and
ﬁbroblast proliferation
Epidermal growth factor; EGF 4q25
Induces diﬀerentiation of speciﬁc cells, is a potent
mitogenic factor for a variety of cultured cells of
both ectodermal and mesodermal origin
Vascular endothelial growth factor A; VEGFA 6p21.1 Is a mitogen primarily for vascular endothelial cells,
induces angiogenesis
Vascular endothelial growth factor B; VEGFB 11q13.1 I sar e g u l a t o ro fb l o o dv e s s e lp h y s i o l o g y ,w i t har o l e
in endothelial targeting of lipids to peripheral tissues
Vascular endothelial growth factor C; VEGFC 4q34.3 Angiogenesis and endothelial cell growth, and can
also aﬀect the permeability of blood vessels
Includes,name,cytogeneticlocation,andbiologicactivitiesofplateletgrowthfactors.Furthermore,PRPcontentotherproteinslikeinterleukin-8,macrophage
inﬂammatory protein-1 alpha, and platelet factor-4.
applications; for topical therapy of various clinical condi-
tions, including wounds and soft tissue injuries; and suitable
alternative to fetal calf serum for the expansion of mesenchy-
mal stem cells from adipose tissue (see Table 1)[ 9–12].
In this paper we are going to talk about the platelets,
platelet-derived particles, and their biological eﬀects in re-
generative medicine.
2.Platelets
Platelets are the ﬁrst element to arrive at the site of tissue
injury and are particularly active in the early inﬂammatory
phases of the healing process [6]. They play a role in aggre-
gation, clot formation, homeostasis through cell membrane
adherence, and release of substances that promote tissue
repair and that inﬂuence the reactivity of blood vessels
and blood cell types involved in angiogenesis, regeneration,
and inﬂammation [13]. Platelet secretory granules contain
growth factors (GFs), signaling molecules, cytokines, inte-
grins, coagulation proteins, adhesion molecules, and some
other molecules, which are synthesized in megakaryocytes
and packaged into the granules through vesicle traﬃck-
ing processes [14]. Three major storage compartments in
platelets are alpha granules, dense granules, and lysosomes
[14].
Platelets mediate these eﬀects through degranulation, in
which platelet-derived GF (PDGF), insulin-like GF (IGF1),
transforming GF-beta 1 (TGF-β1), vascular endothelial GF
(VEGF), basic ﬁbroblastic GF (bFGF), and epidermal GF
(EGF) are released from alpha granules [15]. In fact, the
majority of the platelet substances are contained in alpha
granules(seeTable2)[ 15]. When platelets are activated, they
exocytose the granules; this process is mediated by molecular
mechanisms homologous to other secretory cells, uniquely
coupled to cell activation by intracellular signaling events
[16].
Among bioactive molecules stored and released from
platelets dense granules are catecholamines, histamine, sero-
tonin, ADP, ATP, calcium ions, and dopamine, which are
active in vasoconstriction, increased capillary permeability,
attract and activate macrophages, tissue modulation and
regeneration. These non-GF molecules have fundamental
eﬀects on the biologic aspects of wound healing [5].
For their numerous functions, platelets have developed
a set of platelet receptors that are the contact between
platelets and their surroundings; they determine the reac-
tivity of platelets with a wide range of agonists and adhe-
sive proteins. Some of these receptors are expressed only
on activated platelets [6]. Certain biological mechanisms
present in the platelets are shared with other cells, and
therefore they contain some common cytoplasmic enzymes,
signal transduction molecules, and cytoskeletal components
[14].International Journal of Peptides 3
Table 2: Some bioactive peptides present in the alpha granules of platelets.
General activity categories Speciﬁc molecules Cytogenetic
location Biologic activities
Tissue factor pathway
inhibitor; TFPI 2q32.1 Regulates the tissue factor-(TF-) dependent
pathway of blood coagulation
Kininogen; KNG 3q27.3 Plays an important role in assembly of the
plasma kallikrein
Growth arrest-speciﬁc 6;
GAS6 13q34 Stimulates cell proliferation
Multimerin; MMRN 4q22 Carrier protein for platelet factor V
Clotting factors and related proteins Antithrombin; AT 1q25.1 Is the most important inhibitor of thrombin
Protein S; PROS1 3q11.1 Inhibits blood clotting
Coagulation factor V; F5 1q24.2 Acts as a cofactor for the conversion of pro-
thrombin to thrombin by factor Xa
Coagulation factor XI; F11 4q35.2
It participates in blood coagulation as a cat-
alyst in the conversion of factor IX to factor
IXa in the presence of calcium ions
Plasminogen; PLG 6q26 Induces plasmin production (leads to ﬁbrin-
olysis)
Plasminogen activator
inhibitor 1; PAI1 7q22.1 Regulation of plasmin production
Alpha-2-plasmin inhibitor 17p13.3 Inactivation of plasmin
Fibrinolytic factors and related proteins Osteonectin; ON 5q33.1 Inhibits cell-cycle progression and inﬂuences
the synthesis of extracellular matrix (ECM)
Histidine-rich glycoprotein;
HRG 3q27.3 Interacts with heparin and thrombospondin
Thrombin-activatable
ﬁbrinolysis inhibitor; TAFI 13q14.13 Attenuates ﬁbrinolysis
Alpha-2-Macroglobulin; A2M 12p13.31 Carrier of speciﬁc growth factors and indu-
ces cell signaling
Tissue inhibitor of
metalloproteinase 4; TIMP4 3p25.2
Inhibits matrix metalloproteinases (MMPs),
a group of peptidases involved in degrada-
tion of the extracellular matrix
Complement component 1
inhibitor; C1NH 11q12.1
Inhibits serine proteinases including plas-
min, kallikrein, and coagulation factors XIa
and XIIa
Proteases and antiproteases Alpha-1-antitrypsin (serpin
peptidase inhibitor) 14q32.13 Acute phase protein, inhibits a wide variety
of proteases and enzymes
Nexin 2; SNX2 5q23.2 Modulates intracellular traﬃcking of pro-
teins to various organelles
Platelet factor 4; PF4 4q13.3 Inhibition of angiogenesis
Basic proteins
β-thromboglobulin
(Pro-platelet basic protein;
PPBP)
4q13.3 Plateletactivation,inhibitionofangiogenesis
Endostatin (Collagen, type
XVIII, Alpha-1; COL18A1) 21q22.3 Inhibitors of endothelial cell migration and
angiogenesis
Fibrinogen; FG 4q31.3 Blood clotting cascade (ﬁbrin clot forma-
tion)
Fibronectin; FN 2q35
Binds to cell-surface integrins, aﬀecting cell
adhesion, cell growth, migration, and differ-
entiation
Adhesive proteins Vitronectin; VTN 17q11.2 Induces cell adhesion, chemotaxis
Thrombospondin I; THBS1 15q14 Inhibition of angiogenesis
Laminin-8 18p11.31-
p11.23 Modulates cell contact interactions
It is described general activity categories, speciﬁc molecules, cytogenetic location and biologic activities. Furthermore, alpha granules include growth factors
of Table 1, membrane glycoproteins, and others proteins like albumin and immunoglobulins.4 International Journal of Peptides
The platelet lifespan is approximately 7 to 9 days, which
they spend circulating in the blood in their resting form.
When adhered to exposed endothelium or activated by
agonists, they change their shape and secrete the contents
of the granules (including ADP, ﬁbrinogen, and serotonin),
whichisfollowedbyplateletaggregation[7].Initiationofthe
signaling event within the platelet leads to the reorganization
of the platelet cytoskeleton, which is visible as an extremely
rapid shape change [17].
3.Platelet-RichPlasma (PRP)
Platelets are activated either by adhesion to the molecules
that are exposed on an injured endothelium, such as von
WillebrandFactor(vWF),collagen,ﬁbronectin,andlaminin,
or by physiologic agonists such as thrombin, ADP, collagen,
thromboxane A2, epinephrine, and platelet-activating fac-
tors [18].
PRP has been used clinically in humans since the 1970s
for its healing properties attributed of autologous GF and
secretory proteins that may enhance the healing process on
a cellular level [19]. Furthermore, PRP enhances the recruit-
ment, proliferation, and diﬀerentiation of cells involved in
tissue regeneration [20]. PRP-related products, also known
as platelet-rich concentrate, platelet gel, preparation rich in
growth factors (PRGF), and platelet releasate, have been
studied with in vitro and in vivo experiments in the ﬁelds
of surgical sciences mainly [21].
Depending on the device and technique used, PRP can
contain variable amounts of plasma, erythrocytes, white
blood cells, and platelets. The platelet concentration should
be increased above baseline or whole blood concentration. It
isgenerallyagreeduponthatPRPshouldhaveaminimumof
5 times the number of platelets compared to baseline values
for whole blood to be considered “platelet rich” [22].
This conclusion is supported by in vitro work showing a
positive dose-response relationship between platelet concen-
tration and proliferation of human mesenchymal stem cells,
proliferation of ﬁbroblasts, and production of type I collagen
[23]. This suggests that the application of autologous PRP
can enhance wound healing, as has been demonstrated in
controlled animal studies for both soft and hard tissues
[24, 25].
Autologous PRP represents an eﬃcacious treatment for
its use in wound healing like chronic diabetic foot ulceration
due to multiple growth factors, is safe for its autologous
nature, and is produced as needed from patient blood. Like
we said, key for self-regeneration [26].
Upon activation, platelets release their granular contents
into the surrounding environment. The platelet alpha gran-
ules are abundant and contain many of the GFs responsible
for the initiation and maintenance of the healing response
[14].TheseGFshavebeenshowntoplayanimportantrolein
all phases of healing. The active secretion of these proteins by
platelets begins within 10 minutes after clotting, with more
than 95% of the presynthesized GFs secreted within 1 hour.
After this initial burst, the platelets synthesize and secrete
additional proteins for the balance of their life (5–10 days)
[10].
The ﬁbrin matrix formed following platelet activation
also has a stimulatory eﬀect on wound healing. The ﬁbrin
matrixformsbypolymerizationofplasmaﬁbrinogenfollow-
ing either external activation with calcium or thrombin or
internal activation with endogenous tissue thromboplastin
[23]. This matrix traps platelets allowing a slow release of
a natural combination of GF while providing a provisional
matrix that provides a physical framework for wound stem
cells and ﬁbroblast migration and presentation of other
biological mediators such as adhesive glycoproteins [27, 28].
PRP with a platelet concentration of at least
1000000platelets/μLin5mLofplasmaisassociatedwiththe
enhancement of healing [29]. PRP can potentially enhance
healing by the delivery of various GF and cytokines from
the alpha granules contained in platelets and has an 8-fold
increase in GF concentrations compared with that of whole
blood [30].
The use of PRP to enhance bone regeneration and soft
tissue maturation has increased dramatically in the ﬁelds
of orthopedics, periodontics, maxillofacial surgery, urology,
andplasticsurgeryoverthelastyears.However,controversies
exist in the literature regarding the added beneﬁt of this
procedure. While some authors have reported signiﬁcant
increases in bone formation and maturation rates [21],
others did not observe any improvement [31].
The wound-healing process is a complex mechanism
characterized by four distinct, but overlapping, phases: he-
mostasis, inﬂammation, proliferation, and remodeling [8].
The proliferative phase includes blood vessel formation by
endothelial cells and bone synthesis by osteoblasts. All these
eventsarecoordinatedbycell-cellinteractionsandbysoluble
GF released by various cell types. Recent reviews have em-
phasized the need for additional research aiming to charac-
terize PRP in terms of GF content and their physiological
roles in wound healing [32–34].
Thrombin represents a strong inducer of platelet activa-
tion leading to GF release [35]. It is also known that par-
ticulate grafts, when combined with calcium and thrombin
treated PRP, possess better handling characteristics and
higher GF content [31]. Typically, thrombin concentrations
used in clinical applications vary between 100 and 200 units
per mL [21], while platelet aggregation is maximum in the
range of 0.5 to 4 units per mL [36].
The basic cytokines identiﬁed in platelets play important
roles in cell proliferation, chemotaxis, cell diﬀerentiation,
regeneration, and angiogenesis [28]. A particular value of
PRP is that these native cytokines are all present in “normal”
biologic ratios. The platelets in PRP are delivered in a clot,
which contains several cell adhesion molecules including
ﬁbronectin, ﬁbrin, and vitronectin. These cell adhesion
molecules play a role in cell migration and thus also add
to the potential biologic activity of PRP. The clot itself can
also play a role in wound healing by acting as conductive
matrix or “scaﬀold” upon which cells can adhere and begin
the wound-healing process [28].
PRPcanonlybemadefromanticoagulatedblood.Prepa-
ration of PRP begins by addition of citrate to whole blood
to bind the ionized calcium and inhibit the clotting cascade
[15]. This is followed by one or two centrifugation steps. TheInternational Journal of Peptides 5
ﬁrst centrifugation step separates the red and white blood
cells from plasma and platelets. The second centrifugation
step further concentrates the platelets, producing the PRP
separate from platelet-poor plasma [19].
An important point is that clotting leads to platelet acti-
vation, resulting in release of the GF from the alpha granules,
otherwise known as degranulation. Approximately 70% of
the stored GFs are released within 10 minutes, and nearly
100% of the GFs are released within 1 hour. Small amounts
ofGFmaycontinuetobeproducedbytheplateletduringthe
rest of its lifespan (1 week) [21].
A method to delay the release of GF is possible by addi-
tion of calcium chloride (CaCl2) to initiate the formation
of autogenous thrombin from prothrombin. The CaCl2 is
added during the second centrifugation step and results
in formation of a dense ﬁbrin matrix. Intact platelets are
subsequently trapped in the ﬁbrin matrix and release GF
slowly over a 7-day period. The ﬁbrin matrix itself may also
contribute to healing by providing a conductive scaﬀold for
cell migration and new matrix formation [27].
4. GrowthFactors(GFs)
Platelets are known to contain high concentrations of diﬀer-
ent GF and are extremely important in regenerative process;
activation of the platelet by endothelial injury initiates the
wound-healing process [30]. When platelets are activated,
their alpha granules are released, resulting in an increased
concentration of GF in the wound milieu [14].
There is increasing evidence that the platelet cell mem-
branes themselves also play a crucial role in wound healing
through their GF receptor sites [28]. GFs are found in a wide
array of cells and in platelet alpha granules [37]. Table 1 gives
an overview of some of the more extensively studied GFs
and their involvement in wound healing. There are many
more, both discovered and undiscovered, GFs. The platelet
is an extremely important cell in wound healing because it
initiates and plays a major role in the wound regenerative
process [38].
The ﬁrst discovered GF was EGF in 1962 by Cohen
[39]. It was not until 1989 before clinical trials with EGF
were attempted to demonstrate enhanced wound healing.
Studies did demonstrate that EGF can accelerate epidermal
regeneration and enhance healing of chronic wounds [40].
PDGF was discovered in 1974 and is ubiquitous in the
body. It is known to be released by platelet alpha granules
during wound healing and stimulate the proliferation of
many cells, including connective tissue cells. In fact, thus far,
high-aﬃnity cell-surface receptors speciﬁc for PDGF have
only been demonstrated on connective tissue cells. When
released, PDGF is chemotactic for monocytes, neutrophils,
and ﬁbroblasts. These cells release their own PDGF, thus
creating a positive autocrine feedback loop [41]. Other
functions of PDGF include eﬀects on cell growth, cellular
migration, metabolic eﬀects, and modulation of cell mem-
brane receptors [42].
PDGFs were ﬁrst identiﬁed as products of platelets which
stimulated the proliferation in vitro of connective tissue cell
types such as ﬁbroblasts [43].
The PDGF system, comprising four isoforms (PDGF-
A, -B, -C, and -D) and two receptor chains (PDGFR-alpha
and -beta), plays important roles in wound healing, ath-
erosclerosis, ﬁbrosis, and malignancy. Components of the
systemareexpressedconstitutivelyorinduciblyinmostrenal
cells [42]. They regulate a multitude of pathophysiologic
events, ranging from cell proliferation and migration to
extracellular matrix accumulation, production of pro- and
anti-inﬂammatory mediators, tissue permeability, and regu-
lation of hemodynamics [43].
Inactivation of PDGF-B and PDGF beta receptor
(PDGFRb) genes by homologous recombination in embry-
onic stem cells shows cardiovascular, hematological, and re-
nal defects. The latter is particularly interesting since it con-
sists of a speciﬁc cellular defect: the complete loss of kidney
glomerular mesangial cells and the absence of urine collec-
tion in the urinary bladder [43].
PDGF-C and PDGFR-alpha contribute to the formation
oftherenalcorticalinterstitium.Almostallexperimentaland
human renal diseases are characterized by altered expression
of components of the PDGF system. Infusion or systemic
overexpression of PDGF-B or -D induces prominent mesan-
gioproliferativechangesandrenalﬁbrosis.Interventionstud-
iesidentiﬁedPDGF-Casamediatorofrenalinterstitialﬁbro-
s i sa n dP D G F - Ba n d- Da sk e yf a c t o r si n v o l v e di nm e s a n g i o -
proliferative disease and renal interstitial ﬁbrosis [43–45].
Fr´ echette et al., demonstrated that the release of PDGF-
B, TGF-beta1, bFGF, and VEGF is signiﬁcantly regulated by
the amount of calcium and thrombin added to the PRP and
that PRP supernatants are more mitogenic for endothelial
cells than whole-blood supernatants [11]. Other GFs such as
epidermal growth factor (EGF), transforming growth factor-
alpha (TGF-alpha), insulin-like growth factor-1 (IGF-1),
angiopoietin-2(Ang-2),andinterleukin-1beta(IL-1beta)are
also known to play important roles in the wound-healing
process [28].
In 2008, Wahlstr¨ om et al., demonstrated that growth
factors released from platelets had potent eﬀects on fracture
and wound healing. The acidic tide of wound healing, that is,
thepHwithinwoundsandfractures,changesfromacidicpH
to neutral and alkaline pH as the healing process progresses
[44]. They investigated the inﬂuence of pH on lysed platelet
concentrates regarding the release of growth factors. The
plateletconcentratesfreeofleukocytecomponentswerelysed
and incubated in buﬀers with pH between 4.3 and 8.6. Bone
morphogenetic protein-2 (BMP-2), platelet-derived growth
factor(PDGF),transforminggrowthfactor-beta(TGF-beta),
and vascular endothelial growth factor (VEGF) were mea-
sured by quantitative enzyme-linked immunosorbent assays.
BMP-2 was only detected in the most acidic preparation (pH
4.3), which is interesting since BMP-2 has been reported
to be an endogenous mediator of fracture repair and to
be responsible for the initiation of fracture healing. These
ﬁndings indicate that platelets release substantial amounts
of BMP-2 only under conditions of low pH, the milieu
associated with the critical initial stage of fracture healing
[44].6 International Journal of Peptides
Recently, Bir et al., demonstrated stromal cell-derived
factor 1-α (SDF-1α) PRP from diabetic mice. The con-
centration (pg/mL) of diﬀerent growth factors was signif-
icantly higher in the PRP group than in the platelet-poor
plasma (PPP) group. The concentrations (pg/mL) of SDF-1α
(10,790 ± 196 versus 810 ± 39), PDGF-BB (45,352 ± 2,698
versus 958 ± 251), VEGF (53±6v e r s u s3 0± 2), bFGF (29 ±
5v e r s u s9±5), and IGF-1 (20,628 ± 1,180 versus 1,214 ±
36) were signiﬁcantly higher in the PRP group than in the
PPP group, respectively [46].
5.PlateletGFasTreatment
5.1. In Vitro Studies. Knowledge of GF and their function
is far from complete. Many of the known functions were
learned through in vitro study. Although many GFs are asso-
ciated with wound healing, PDGF and TGF-β1a p p e a rt ob e
two of the more integral modulators [46]. PDGF has activity
inearlywoundhealing(duringtheacidtide).Invitrostudies
have shown that at lower pH (5.0), platelet concentrate lysate
has increased concentrations of PDGF, with an increased
capacity to stimulate ﬁbroblast proliferation [23]. TGF-β
increases the production of collagenfrom ﬁbroblasts [47].Its
release in vitro is enhanced by neutral or alkaline pH, which
correspond to the later phases of healing [10]. Through
modulation of interleukin-1 production by macrophages,
PRP may inhibit excessive early inﬂammation that could
lead to dense scar tissue formation [48]. Insulin-like GF-I
(IGF-1) has also been extensively studied for its ability to
induce proliferation, diﬀerentiation, and hypertrophy of
multiple cell lines. Separate analyses of GF in PRP have
shown signiﬁcant increases in PDGF, VEGF, TGF-β1, and
EGF, compared with their concentrations in whole blood
[15, 49].
IGF-1 has two important functions: chemotaxis for
vascular endothelial cells into the wound which results in
angiogenesis and promoting diﬀerentiation of several cell
lines including chondroblasts, myoblasts, osteoblasts, and
hematopoietic cells [50].
TGF-β is a member of the newest family of proteins
discovered. Two major sources of this protein are the platelet
and macrophage. TGF-β causes chemotactic attraction and
activation of monocytes, macrophages, and ﬁbroblasts. The
activated ﬁbroblasts enhance the formation of extracellular
matrixandcollagenandalsostimulatethecellsabilitytocon-
tract the provisional wound matrix [51]. Macrophages inﬁl-
tration promotes TGF-β that induces extracellular matrix
such as collagen and ﬁbronectin; however alpha-mangostin
prevents the increase in this molecule in rats with Cisplatin-
induced nephrotoxicity [52].
5.2. In Vivo Studies. In vivo study is much more complex
due to the inability to control the environment. A further
complexingmatteristhefactthatthesameGF,dependingon
the presence or absence of other peptides, may display either
stimulatory or inhibitory activity within the same cell. Also,
a particular GF can alter the binding aﬃnity of another GF
receptor [53].
Release of PDGF can have a chemotactic eﬀect on mono-
cytes, neutrophils, ﬁbroblasts, stem cells, and osteoblasts.
This peptide is a potent mitogen for mesenchymal cells in-
cluding ﬁbroblasts, smooth muscle cells and glial cells [54]
and is involved in all three phases of wound healing, includ-
ing angiogenesis, formation of ﬁbrous tissue, and reepithe-
lialization [41].
TGF beta released from platelet alpha granules is a mito-
gen for ﬁbroblasts, smooth muscle cells, and osteoblasts. In
addition, it promotes angiogenesis and extracellular matrix
production [41]. VEGF promotes angiogenesis and can
promote healing of chronic wounds and aid in endochondral
ossiﬁcation.EGF,anotherplatelet-containedGF,isamitogen
for ﬁbroblasts, endothelial cells, and keratinocytes and also is
useful in healing chronic wounds [55].
IGF, another platelet-contained GF regulates bone main-
tenanceandisalsoanimportantmodulatorofcellapoptosis,
and, in combination with PDGF, can promote bone regener-
ation [56].
However, there are conﬂicting results with regard to IGF-
1, where the majority of studies reported no increase in
IGF-1 in PRP, compared with whole blood. There are also
conﬂicting results regarding the correlation between the GF
content and platelet counts in PRP [57]. The basis of these
contradictions is not fully understood and may be related
to variability in patient age, health status, or platelet count.
Alternatively, diﬀerences in GF content and platelet count
may be due to the various methods of processing, handling,
and storing of samples, in addition to the type of assay
performed. The diversity of PRP products should be taken
into account when interpreting and comparing results and
methods for generating PRP [10].
VEGF, discovered 25 years ago, was initially referred to
as vascular permeability factor [58]. In mammals, there are
at least four members of the VEGF family: VEGF-A, VEGF-
B, and the VEGF-C/VEGF-D pair, which has a common
receptor, VEGF receptor 3 (VEGF-R3) [59]. VEGF-A is
a proangiogenic cytokine during embryogenesis and con-
tributes to vascular integrity: selective knockout of VEGF-A
in endothelial cells increases apoptosis, which compromises
the integrity of the junctions between endothelial cells [60,
61]. VEGF-B, which can form heterodimers with VEGF-
A, occurs predominantly in brown fat, myocardium, and
skeletal muscle [62]. VEGF-C and VEGF-D seem to regulate
lymphangiogenesis. The expression of VEGF-R3 in adults
is restricted to the lymphatics and fenestrated endothe-
lium [63]. Neuropilin 1 and neuropilin 2 are receptors
that bind speciﬁc VEGF family members and are impor-
tant in neuronal development and embryonic vasculogenesis
[64].
Megakaryocytes and platelets contain the three major
isoforms of VEGF-A; after exposure to thrombin in vitro,
theyreleaseVEGF-A[65–67].VEGF-Aalterstheendothelial-
cell phenotype by markedly increasing vascular permeability,
upregulating expression of urokinase, tissue plasminogen
activator, connexin, osteopontin, and the vascular-cell adhe-
sion molecule [68].International Journal of Peptides 7
Table 3: Platelet-plasma-derived peptides are current in clinical use and clinical trials.
Year Researchers Health problems Clinical protocols Level of evidence Results
2005 Carreon et al.
Bone healing in
instrumented
posterolateral
spinal fusions
Retrospective cohort study to
evaluate rates of nonunionin
patients (n = 76) with
autologous iliac bone graft
augmented with platelet gel
Level 4, case control
group of 76 randomly
selected patients who were
matched and grafted with
autogenous iliac bone
graft with no platelet gel
Nonunion rate in platelet
gel group was 25%; 17% in
control group (P = .18)
2006
Mishra and
Pavelko
Chronic elbow
tendinitis
Cohort, 15 patients injected
with PRP Level 2, 5 controls
Decreased pain at 2 years
(measured by visual analog
pain score)
Savarino et
al.
Bone healing in
v a r u sH T O sf o r
genu varus
Randomized case control, 5
patients with bone grafted with
bone chips and PRP
Level 4, 5 controls bone
grafted without PRP
No functional or clinical
diﬀerence; histology shows
increased amounts of
osteoid and osteoblasts in
PRP group
S´ anchez et al. Achilles tear
healing
Case control, 6 repairs with
PRP
Level 3, 6 matched
retrospective controls
Improved ROM and early
return to activity with PRP
by ± 4–7 weeks
2007 Dallari et al.
Bone healing in
v a r u sH T O sf o r
genu varus
Prospective randomized
control: group A, bone chips
with platelet gel (n = 11); group
B, bone chips, BMC, and
platelet gel (n = 12)
Level 1, 10 controls
treated with bone chips
only
Biopsies at 6 weeks after
surgery showed increased
osteoid and osteoblasts in
groups A and B;
radiographic diﬀerences
decreased with time; no
clinical diﬀerence at 1 year
among groups
Kitoh et al.
Bone healing in
distraction
osteogenesis for
limb lengthening
and short stature
Retrospective, comparison case
control; at 3 weeks, patients
injected with expanded BMC
with or without PRP (n = 32
bones)
Level 3, 60 bones in
retrospective control
g r o u p( h i g h%o f
congenital etiologies
versus PRP group)
Average healing in BMC +
PRP was 34±4d/cm;
control group average was
73.4±27d/cm (P = .003)
2009 S´ anchez et al. Bone healing in
nonunions
Retrospective, case series; 16
nonhypertrophic nonunions
treated with either surgery and
PRGF or percutaneous
i n j e c t i o n so fP R G Ft os t i m u l a t e
(n = 3) without surgery
Level 4, no control group
84% healed after surgical
treatment; unclear if PRGF
made a diﬀerence
Some published human clinical orthopaedic PRP studies. PRP: platelet-rich plasma; ROM: range of motion; HTO: high tibial osteotomy; BMC: bone marrow
cells; PRGF: preparation rich in growth factors [27]. Taken from Foster et al. [27].
6. PRP in CellTherapy and
Regenerative Medicine
PRP can be combined with cell-based therapies such as
adipose-derived stem cells, regenerative cell therapy, and
transfer factors therapy [69]. While this is a relatively new
concept, the strategy is appealing as the regenerative matrix
graft delivers a potent trilogy of regenerative cells, ﬁbrin
matrix, and GF [15]. The applications are similar to those
for PRP alone with the added beneﬁt of regenerative cell
enrichment.
Verrier et al., demonstrated that cultures of human mes-
enchymal stem cell (MSC) supplemented with platelet-
released supernatant (PRS) had diﬀerentiation towards an
osteoblastic phenotype in vitro possibly mediated by bone
morphogenetic protein-2 (BMP-2). PRS showed an osteoin-
ductive eﬀect on MSC, as shown by an increased expression
of typical osteoblastic marker genes such as collagen I, bone
sialoprotein II, BMP-2, and matrix metalloproteinase-13
(MMP-13), as well as by increased Ca++ incorporation [70].
Furthermore, the role of platelets in hemostasis may
be inﬂuenced by alteration of the platelet redox state, the
presence of endogenous or exogenous antioxidants, and the
formation of reactive oxygen and nitrogen species [71]. As
discussed by Sobotkov´ ae ta l . ,[ 71], trolox and resveratrol
inhibit aggregation of washed platelets and PRP activated
by ADP, collagen, and thrombin receptor-activating peptide.
Antioxidants, apart from nonspeciﬁc redox or radical-
quenching mechanisms, inhibit platelet activation also by
speciﬁc interaction with target proteins. In this context,
powerful natural antioxidants, like nordihydroguaiaretic
acid (NDGA) extracted from Larrea tridentata [72], S-
allylcysteine (SAC), the most abundant organosulfur com-
pound in aged garlic extract (AG) [73], sulforaphane (SFN),
an isothiocyanate produced by the enzymatic action of
myrosinase on glucoraphanin, a glucosinolate contained in8 International Journal of Peptides
cruciferous vegetables [74], and acetonic and methanolic
extracts of Heterotheca inuloides, can be administered with
ample safety margin in patients treated with PRP [75].
7. Advantages, Limitations,andPrecautions
PRP as autologous procedure eliminates secondary eﬀects
and unnecessary risks for chemically processed strange
molecules, is a natural reserver of various growth factors that
can be collected autologously, and is costeﬀective [76–81]
(see Table 3). Thus for clinical use, no special considera-
tions concerning antibody formation and infection risk are
needed. The key of our health and our own regeneration
resides in our own body. Nevertheless this treatment is not
the panacea, it is only the beginning in this new age of the
regenerativemedicine.Someclinicaldevicestoautomatically
prepare PRPs are available at present. PRP are consistently
being used clinically in the department of orthopedics and
plastic surgery (oral, maxillary facial) for a long time. On the
basis of research evidence, some publications have reported
positive results in either bone or soft tissue healing. It
is recommended to avoid the abuse and use generalized
of this procedure before any disease. Until now, their
clinical applications still are limited. However, some research
concludes that there is no or little beneﬁt from PRP. This
is likely due to faster degradation of growth factors in PRP
since some authors suggest using sustained release form of
PRP to deliver optimal eﬀect of PRP. Gelatin hydrogel is also
being used clinically as a slow, sustained release of carrier for
growth factors in our center recently [47].
8. Conclusions
PRPastherapeuticoptionisapowerfultoolnowadaysforthe
localized delivery of great variety of biologically active GF to
the site of injury and is supported by its simplicity, potential
cost eﬀectiveness, safety, and permanent availability [11].
Platelet concentrates are potentially useful in wound-
healing applications because they function as both a tissue
sealant and a drug delivery system that contains a host of
powerful mitogenic and chemotactic GFs. However, the
method of PRP preparation has a potentially signiﬁcant
impact on the diﬀerent levels of platelet recovery and acti-
vation [10]. Platelet activation during preparation of the
platelet concentrate can result in early alpha granule release
and loss of the GF during the collection process. It is there-
fore critical to recognize that each PRP preparation method
may diﬀer in regard to platelet number, platelet activation
rates, and GF proﬁles [15].
In this regard, therefore, it is critical to deﬁne the extent
of platelet activation that occurs during graft preparation.
If platelets become activated and release the contents of the
alpha granules during the centrifugation process, the GF will
be diluted and lost into the plasma. To ensure that platelets
are intact until the PRP fraction has been collected, platelet
surface marker for platelet activation P selectin can be mea-
sured [30]. However, in all methods, the application of PRP
is really providing a suﬃcient dose of these useful bioactive
peptides for wound healing and regenerative process [82].
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